IAM-K1 / Iambic Therap - LARVOL DELTA

Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference (Businesswire) - "Dr. Miller will detail progress and anticipated milestones for Iambic’s emerging pipeline of development candidates, as well as advances to its AI drug discovery platform. The Company’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs."

Clinical • Oncology • Solid Tumor